<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296461</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-PCL-P01-3002-01</org_study_id>
    <nct_id>NCT04296461</nct_id>
  </id_info>
  <brief_title>Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma</brief_title>
  <official_title>Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UWELL Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UWELL Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1)
      and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell
      non-Hodgkin lymphoma (B-NHL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>A standard 3+3 trial design will be used Welgenaleucel(UWC19) dose escalation cohorts. The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10^6 CAR-T cells/kg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>30 days after infusion</time_frame>
    <description>A standard 3+3 trial design will be used for Welgenaleucel (UWC19) dose escalation cohorts.The dosing of Welgenaleucel (UWC19) will be divided into 5 cohorts, the subjects will receive Welgenaleucel (UWC19) once on day 14-18 after apheresis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>30 days after infusion</time_frame>
    <description>The 3+3 design entails that if one patient out of the first three patients has a DLT, up to three additional patients will be entered at that dose level.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Welgenaleucel (UWC19)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I The safety and efficacy of Welgenaleucel (UWC19) will be evaluated in a standard 3+3 dose escalation approach.The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10^6 CAR-T cells/kg administered intravenously once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Welgenaleucel</intervention_name>
    <description>Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.</description>
    <arm_group_label>Welgenaleucel (UWC19)</arm_group_label>
    <other_name>UWC19</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Have a primary diagnosis of B cell non-Hodgkin lymphoma

        - Histologically confirmed: Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal
        Large B Cell Lymphoma (PMBCL), Transformation Follicular Lymphoma (TFL), High grade B-cell
        Lymphoma (HGBCL), Mantle cell Lymphoma (MANT), Burkitt Lymphoma (BURK), Lymphoblastic
        Lymphoma

          -  Chemotherapy-refractory disease, defined as one of more of the following No response
             to last line of therapy OR Refractory post-autologous stem cell transplant (ASCT)

          -  Individuals must have received adequate prior therapy including at a minimum:

        anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative
        and an anthracycline containing chemotherapy regimen for individual with transformed FL
        must have chemorefractory disease after transformation to DLBCL.

          -  No active infection of HIV, HTLV and Syphilis

          -  Adequate renal function

          -  Adequate hepatic function

          -  Adequate cardiac function

          -  Adequate venous access for apheresis, and no other contraindications for leukapheresis

          -  Voluntary informed consent is given.

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  Received allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

          -  Body weight less than 30 kg

          -  Pregnant or lactating women.

          -  Uncontrolled active infection.

          -  History of hepatitis B or hepatitis C infection.

          -  Previously treatment with any gene therapy products or cell therapy product in past 28
             days.

          -  HIV infection.

          -  Lymphoma with central nervous system (CNS) involvement

          -  Have autoimmune disorders

          -  Have active infection or inflammatory disorders

          -  Prescreening test results in expansion rate less than 5 folds

          -  An allergy to gentamycin and/or streptomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheng-Yi Kuo, PhD</last_name>
    <phone>+886-2-26972200</phone>
    <phone_ext>202</phone_ext>
    <email>jerry.kuo@uwell.com.tw</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>CAR-T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

